|
Post by lakers on Sept 10, 2019 21:48:26 GMT -5
SO said keep an eye on "CG". Unfortunately, I doubt CG stands for "Calcitonin Gene-related". Regardless, I like the summary of comments and possible partnership opportunities. To your point about "cracking the code", the emphasis on testing CGRP for migraine relief is reminiscent of Dr. Castagna's early comments on Treprostinil... There are three CGRP inhibitors currently on the market and they are all monoclonal antibodies. A quick google indicates that mabs are not absorbed well through the lungs. Also, they are given subcutaneously monthly or quarterly so inhalation would not offer much benefit. There is a new class of drugs called gepants which are small molecule drugs that block the CGRP receptor. They are being investigated for both migraine relief and prevention. The oral gepants have had problems with liver toxicity and might be good candidates for inhalation. It has to be an FDA approved compound in bucket 1. Hence, gepants don’ qualify.
|
|